News
MyChesCo on MSN11h
Windtree Therapeutics Unveils U.S. Exclusivity Strategy for IstaroximeWARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced its strategy to secure 7.5 years of U.S. exclusivity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback